Journal article

Nonlinear Distributional Mapping (NoDiM) for harmonization across amyloid-PET radiotracers

Michael J Properzi, Rachel F Buckley, Jasmeer P Chhatwal, Michael C Donohue, Cristina Lois, Elizabeth C Mormino, Keith A Johnson, Reisa A Sperling, Aaron P Schultz

NEUROIMAGE | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2019

Abstract

INTRODUCTION: There is a growing need in clinical research domains for direct comparability between amyloid-beta (Aβ) Positron Emission Tomography (PET) measures obtained via different radiotracers and processing methodologies. Previous efforts to provide a common measurement scale fail to account for non-linearities between measurement scales that can arise from these differences. We introduce a new application of distribution mapping, based on well established statistical orthodoxy, that we call Nonlinear Distribution Mapping (NoDiM). NoDiM uses cumulative distribution functions to derive mappings between Aβ-PET measurements from different tracers and processing streams that align data bas..

View full abstract

Grants

Awarded by National Institutes of Health


Awarded by Center for Functional Neuroimaging Technologies


Awarded by NIH Shared Instrumentation Grant Program and/or High-End Instrumentation Grant Program


Awarded by Alzheimer's Disease Neuroimaging Initiative (ADNI) National Institutes of Health


Awarded by DOD ADN


Awarded by NATIONAL CENTER FOR RESEARCH RESOURCES


Awarded by NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING


Awarded by NATIONAL INSTITUTE ON AGING


Funding Acknowledgements

Special thanks to Dr. Bob Koeppe, Dr. Bill Klunk, and Dr. Julie Price for their discussion and advice.for the Alzheimer's Disease Neuroimaging Initiative*, and the Australian Imaging Biomarkers and Lifestyle flagship study of ageing***Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc. edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni. loni.usc.edu/wpcontent/ uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.**Data used in the preparation of this article was obtained from the Australian Imaging Biomarkers and Lifestyle flagship study of ageing (AIBL) funded by the Commonwealth Scientific and Industrial Research Organisation (CSIRO) which was made available at the ADNI database (www.loni.usc.edu/ADNI). The AIBL researchers contributed data but did not participate in analysis or writing of this report. AIBL researchers are listed at www.aibl.csiro.au.This work was supported with funding from the National Institutes of Health [P01 AG036694 (Sperling and Johnson)]. This research was carried out in part at the Athinoula A. Martinos Center for Biomedical Imaging at the Massachusetts General Hospital, using resources provided by the Center for Functional Neuroimaging Technologies [P41EB015896], a P41 Biotechnology Resource Grant supported by the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health. This work also involved the use of instrumentation supported by the NIH Shared Instrumentation Grant Program and/or High-End Instrumentation Grant Program [S10RR021110, S10RR023401, and S10RR023043]. For ADNI, data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) National Institutes of Health Grant [U01 AG024904] and DOD ADNI (Department of Defense award number [W81XWH-12-2-0012]). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organisation is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.